<DOC>
	<DOCNO>NCT02072291</DOCNO>
	<brief_summary>The main factor associate pregnancy rate In Vitro Fertilization ( IVF ) treatment embryo quality uterine ability accept embryo implantation . This ability influence uterine contraction ( UC ) , change pattern direction menstrual cycle . An abnormal uterine contraction pattern displace embryo proper position uterine cavity towards cervix fallopian tube result may decrease pregnancy rate increase risk ectopic pregnancy . Indeed , previous study demonstrate negative correlation uterine contraction rate implantation/pregnancy rate . Suppression uterine contraction embryo transfer achieve large array drug , cyclo-oxygenase inhibitor , Î²2-adrenoreceptor agonist , calcium-channel blocker , phosphodiesterase inhibitor oxytocin antagonist . The objective study evaluate efficacy Nifedipine administration reduce uterine contractility IVF-frozen embryo transfer ( FET ) treatment .</brief_summary>
	<brief_title>Nifedipine Treatment Uterine Contractility IVF</brief_title>
	<detailed_description />
	<mesh_term>Nifedipine</mesh_term>
	<criteria>Patient undergo frozen embryo transfer Body mass index ( BMI ) &gt; 38 kg/m2 Early follicular phase ( day 24 ) serum follicle stimulate hormone ( FSH ) level &gt; 20 mIU/ml . Abnormal uterine cavity evidence sonohysterogram hysterosalpingography Any contraindication pregnant carry pregnancy term . Contraindication use nifedipine , Estrogen Progesterone suppository . Patient treat drug interact cytochrome P450 activity : azole antifungal , cimetidine , cyclosporine , erythromycin , quinidine , terfenadine , warfarin , benzodiazepine , flecainide , imipramine , propafenone theophylline . Irregular heart beat already treat another medication high blood pressure . Any ovarian abdominal abnormality may interfere adequate transvaginal sonography ( TVS ) evaluation . Administration investigational drug within three month prior study enrollment . Patient able communicate adequately investigator comply requirement entire study . Unwillingness give write informed consent . Previous entry study simultaneous participation another clinical trial .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>